Veeda Oncology, a global Oncology CRO with facilities in India, North America and Europe, has bagged clinical research programs worth $10.2 million during the last one month from five new clients.

The awarded work includes services for site management, project management, data management, pharmacovigilance, medical oversight, biostatistical support and monitoring services. The work will be conducted in North America, Europe and India.

According to Matt Bowman, president and CEO of Veeda Oncology, ?this continued growth is a reflection of the need within oncology clinical development for oncology expertise, cost effective programs and access to oncology patients?.

Veeda Oncology is a global Oncology CRO with operations in India, Eastern Europe, Western Europe and the US. The company is a full service Oncology CRO for Phase I through Phase IV studies with the unique capability of providing rapid and strong global patient accrual with an effective cost structure.

Veeda Oncology is part of the Veeda Group that includes Veeda Clinical Research (Veeda CR), which is a leading CRO specializing in the early clinical development of drugs. With state-of-the-art clinical pharmacology units in the UK, Europe and India, fully accredited GLP laboratories and an established Biometrics team in Belgium and India, Veeda CR is able to offer clients a full range of phase I and IIa services.